Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avandia (Rosiglitazone) Added to Sulphonylurea in Type 2 Diabetes
NCT01706211Phase 3Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Oct 1998
- Primary completion
- Apr 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Avandia + Sulphonylurea with Placebo + Sulphonylurea (2 arms). Primary endpoints: Hemoglobin A1c at 24 weeks and Fasting Plasma Glucose at 24 weeks. Started Oct 1998; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01706211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706211.